Ingredient or product comparison
GHK-Cu vs Minoxidil vs Finasteride: Mechanism Comparison
GHK-Cu (topical/injectable) TGF-beta 2 suppression + VEGF upregulation 8–12 weeks Unclear (longest trial: 12 weeks) Minimal. Rare scalp irritation at >0.1% concentration Mechanistically sound for miniaturization reversal; limited long-term data. Best as adjunc
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu (topical/injectable)
- TGF-beta 2 suppression + VEGF upregulation
- 8–12 weeks
- Unclear (longest trial: 12 weeks)
- Minimal. Rare scalp irritation at >0.1% concentration
- Mechanistically sound for miniaturization reversal; limited long-term data. Best as adjunct to established therapies.
- Minoxidil 5%
- Prostaglandin synthesis + potassium channel opening
- 12–16 weeks
- Lifelong daily application required
- Scalp irritation (10–15%), unwanted facial hair growth (women), rare cardiovascular effects
- Gold-standard efficacy; rebound shedding occurs within 3–6 months of discontinuation.
- Finasteride 1mg oral
- 5-alpha reductase inhibition (blocks DHT conversion)
- 12–24 weeks
- Lifelong daily dosing required
- Sexual dysfunction (2–4%), depression/anxiety (1–2%), post-finasteride syndrome (rare)
- Most effective single-agent therapy for male pattern baldness; side effect risk limits universal use.
- Platelet-Rich Plasma (PRP)
- Growth factor delivery (PDGF, VEGF, IGF-1)
- 12–16 weeks (requires 3–4 sessions)
- Quarterly maintenance sessions
- Pain/bruising at injection sites; no systemic effects
- Variable outcomes dependent on platelet concentration and processing protocol. Evidence moderate.
- This table shows GHK-Cu studied hair loss fits a specific niche: patients seeking mechanistic alternatives to hormonal or prostaglandin-based therapies. It doesn't replace finasteride or minoxidil. It complements them by targeting follicle cycling through a distinct pathway.